Pfizer and Valneva's Lyme Vaccine Misses Primary Endpoint But Pursue Regulatory Approval on March 23, 2026 Clinical Research Lyme Disease Pfizer regulatory approval Vaccine Efficacy Vaccines Valneva VALOR +